
NuView Life Sciences: Precision cancer diagnostics and medical imaging for urgent medical needs.
NuView Life Sciences, founded with a mission to revolutionize cancer diagnostics and treatment, focuses on developing next-generation oncology products. As a clinical-stage radiopharmaceutical company, NuView is dedicated to addressing urgent and unmet medical needs through precision innovation in medical imaging and diagnostics. Their core offerings include advanced radiopharmaceuticals designed for both the detection and treatment of cancer, positioning them as a leader in the emerging field of Theranostics.
Notable figures associated with NuView Life Sciences include key industry experts and seasoned professionals in the medical imaging and radiopharmaceutical sectors. The company has garnered significant attention from investors interested in cutting-edge cancer therapies. Among its achievements, NuView has made strides in developing proprietary small molecule radiopharmaceuticals that enhance the accuracy and efficacy of cancer diagnostics and treatment. Their impact is marked by a commitment to improving patient outcomes through innovative medical solutions.

Nucleus RadioPharma
nucleusrad.com

Illumina Radiopharmaceuticals

Radionetics Oncology
radionetics.com

NueVue Solutions

Navidea Biopharmaceuticals
navidea.com

Radiomedix
radiomedix.com

Oncurie
oncurie.com

Nuveta
nuveta.com

NanoPharmaceuticals

Mariana Oncology

Radiosight
radiosight.com

Precision Theranostics

Aktis Oncology
aktisoncology.com

nView medical
nviewmed.com

NuProbe
nuprobe.com
Companies similar to NuView Life Sciences include Nucleus RadioPharma, Illumina Radiopharmaceuticals, Radionetics Oncology and NueVue Solutions.
NuView Life Sciences was founded in 2005.
NuView Life Sciences' headquarters is located in South Snyderville Basin, UT, US.
NuView Life Sciences' most recent funding round was for $90M (USD) in August 2020.
As of Aug 3, 2020, NuView Life Sciences has raised a total of $90M (USD).
NuView Life Sciences has 10 employees as of Feb 4, 2024.